Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of iberdomide maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma
2020-003091-40Phase 2Active
- Sponsor
- European Myeloma Network
- Start
- Nov 2020
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of iberdomide in multiple myeloma (MM) (3 arms), sponsored by European Myeloma Network. Primary endpoint: Response improvement rate within 6 months. Started Nov 2020; status: active.
02
Drugs
iberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2020-003091-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003091-40.